Unlock instant, AI-driven research and patent intelligence for your innovation.

A kind of siRNA that specifically inhibits the expression of echs1 gene and its application

A gene expression and gene technology, applied in the field of siRNA, can solve the problems of high price, slow molding speed, poor model stability, etc., and achieve the effect of promoting growth and increasing lipid droplets

Active Publication Date: 2011-12-21
INST OF RADIATION MEDICINE ACAD OF MILITARY MEDICAL SCI OF THE PLA
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The reduction of ECHS1 expression may lead to NAFLD, but there is no report on the relationship between ECHS1 and non-alcoholic fatty liver. The use of RNAi technology to study the mechanism of ECHS1 in the pathogenesis of NAFLD is an important supplement to the pathogenesis of NAFLD
[0006] The existing animal models of non-alcoholic fatty liver disease, such as ob / ob, db / db mice and Obese Zucker rats and other genetically derived spontaneous animal models, mostly need to be imported from abroad, are expensive, and require high feeding conditions , and these animal models cannot spontaneously reproduce non-alcoholic steatohepatitis due to the lack of leptin gene; while the non-alcoholic fatty liver disease animal model reproduced by feeding SD rats with a high-fat diet can reproduce non-alcoholic fatty liver disease steatohepatitis, but the molding speed is slow, generally takes about six months, and the stability of the model is not good

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of siRNA that specifically inhibits the expression of echs1 gene and its application
  • A kind of siRNA that specifically inhibits the expression of echs1 gene and its application
  • A kind of siRNA that specifically inhibits the expression of echs1 gene and its application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] Embodiment 1, siRNA design and synthesis

[0031] 1. Synthesis of ECHS1 siRNA

[0032]The full-length sequence of mouse ECHS1 mRNA (NM 053119.2; sequence 3 in the sequence table) was obtained from the database of the National Center for Biotechnology Information (NCBI) in the United States. According to the principle of RNAi, combined with design software, on the basis of experiments, the design, synthesis and An effective 21nt siRNA targeting mouse ECSH1 gene was screened out. A BLAST comparison check was performed to ensure that there was no homology to other genes.

[0033] The sequence of ECHS1 siRNA is: 5'-GCCUUUGAGAUGACGUUAAtt-3' (sense strand) (sequence 1);

[0034] 3'-gtCGGAAACUCUACUGCAAUU-5' (antisense strand) (SEQ ID NO: 2).

[0035] Chemical synthesis was carried out by Shanghai Gemma Pharmaceutical Technology Co., Ltd. (factory address: 602, No. 1011 Halei Road, Zhangjiang, Pudong, Zip Code: 201203): using NTP as raw material, using ABI...

Embodiment 2

[0040] Example 2, Effect of ECHS1 siRNA on the expression of ECHS1 gene in AML-12 cells in vitro

[0041] 1. Group transfection

[0042] Spread AML-12 cells evenly in a 24-well plate and divide them into 4 groups:

[0043] High-fat experimental group: containing 10% (volume percentage) inactivated newborn bovine serum, 100U / ml penicillin and 100mg / ml streptomycin, sodium oleate of 666 μ mol / L and sodium palmitate of 333 μ mol / L DMEM / F12 medium; transfect 200 pmol of ECHS1 siRNA of Example 1.

[0044] High-fat control group: containing 10% (volume percentage) inactivated newborn bovine serum, 100U / ml penicillin and 100mg / ml streptomycin, sodium oleate of 666 μ mol / L and the sodium palmitate of 333 μ mol / L DMEM / F12 medium; 200 pmol negative control siRNA of Example 1 was transfected.

[0045] Normal experimental group: DMEM / F12 medium containing 10% (volume percent) inactivated neonatal bovine serum, 100 U / ml penicillin and 100 mg / ml streptomycin; transfected with 200 pmol of...

Embodiment 3

[0051] Example 3, Effect of ECHS1 siRNA on AML-12 Cell Steatosis in Vitro

[0052] 1. Group transfection

[0053] AML-12 cells were spread evenly in 12-well plates and divided into 4 groups. Concrete grouping is with the step one of embodiment 2.

[0054] 2. The effect of ECHS1 siRNA on lipid change of AML-12 cells in vitro

[0055] The cells after step 1 were subjected to the following experiments 1 or 2 or 3, respectively.

[0056] 1. Oil red dyeing

[0057] Add 4% paraformaldehyde to a 12-well plate and fix at 4°C for 30 min, wash twice with distilled water and then add oil red O dilution (oil red O 0.5g dissolved in isopropanol 100ml saturated solution and distilled water by 3: 2 diluted, left to stand for 5-10min and filtered for use), dark stained for 10-15min, washed once with 60% ethanol and differentiated under the microscope until the interstitium was clear, washed twice with Mayer’s hematoxylin counterstained nuclei for 8 seconds, washed twice Afterwards, inver...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a siRNA specifically inhibiting the expression of ECHS1 gene and its application. The small interfering RNA provided by the present invention is a double-stranded RNA composed of the nucleotide sequences shown in Sequence 1 and Sequence 2 of the Sequence Listing. The invention provides a siRNA capable of specifically and efficiently inhibiting the expression of the ECHS1 gene and a modified RNA obtained by modifying the siRNA. Both in vitro and in vivo test results show that the RNA provided by the present invention can specifically and efficiently inhibit the expression of ECHS1 gene, promote the increase of free fatty acids, the deposition of triglycerides, and show the increase of lipid droplets. The invention can be applied to the preparation of animal models of nonalcoholic fatty liver disease and the research on the pathogenesis of nonalcoholic fatty liver disease. The present invention is of great value.

Description

technical field [0001] The invention relates to a siRNA specifically inhibiting the expression of ECHS1 gene and its application. Background technique [0002] RNA interference (RNA interference, RNAi) is an evolutionarily conserved defense mechanism against the invasion of transgenes or foreign viruses. Double-stranded RNA (dsRNA) specifically degrades the mRNA in the cell, thereby resulting in the process of effectively blocking the specific gene, which is a sequence-specific post-transcriptional gene silencing (PTGS). RNAi technology has been successfully applied to the study of gene functions in various organisms. Construct siRNA for the target gene, use RNAi technology to shut down the expression of the gene, and analyze the function of the gene according to the change of the phenotype. Gene knockout technology takes a long time to permanently shut down the expression of a certain gene, while RNAi technology can controllably shut down 10 genes within 1 week or even 2 ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12N15/85C12N15/113
CPCA01K2267/0362A01K2217/058C12N9/88A01K67/0275C12N15/1137C12N2310/14A01K2207/05
Inventor 贺福初姜颖厉有名张雪群杨俊涛叶桦虞朝辉孙薇魏汉东
Owner INST OF RADIATION MEDICINE ACAD OF MILITARY MEDICAL SCI OF THE PLA